ロード中...
A Fast and Clean BTK Inhibitor
Bruton’s tyrosine kinase (BTK) is a major drug target for B-cell related malignancies; however, existing BTK inhibitors approved for cancer treatment have significant off-targets that limit their use for autoimmune and inflammatory diseases. Remibrutinib (LOU064) is a novel covalent BTK inhibitor th...
保存先:
| 出版年: | J Med Chem |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Chemical
Society
2020
|
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7304894/ https://ncbi.nlm.nih.gov/pubmed/32401033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.0c00597 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|